New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma
NCT ID NCT03672318
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests a new treatment for multiple myeloma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in the lab to recognize and attack cancer cells carrying a protein called CD138. The main goal is to find the safest dose and check for side effects in 25 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR138 T cells (a type of immune cell engineered to recognize and attack multiple myeloma cells)
- What this could lead to
- If successful, this could lead to a new treatment option for people with multiple myeloma that has not responded to other therapies.
- What could go wrong
- This is an early phase 1 trial with only 25 participants, so it is too small to prove effectiveness. The treatment may cause serious side effects like cytokine release syndrome or prolonged low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE SYSTEM DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Talking about the end: could guided conversations reduce futile cancer treatments?